NcXHF

OLDER WOMEN WITH EARLY-STAGE BREAST CANCER
41. Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with cyclophosphamide
is associated with an overall survival benefıt compared with
doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology
Research Trial 9735. J Clin Oncol. 2009;27:1177-1183.
42. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and
younger women with lymph node-positive breast cancer. JAMA. 2005;
293:1073-1081.
43. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger
patients treated with adjuvant chemotherapy for node-positive breast
cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol.
2007;25:3699-3704.
44. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant
treatment of breast cancer. N Engl J Med. 2008;358:1663-1671.
45. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy
toxicity in older patients: the Chemotherapy Risk Assessment Scale
for High-Age Patients (CRASH) score. Cancer. 2012;118:3377-3386.
46. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity
in older adults with cancer: a prospective multicenter study. J Clin Oncol.
2011;29:3457-3465.
47. Versteeg KS, Konings IR, Lagaay AM, et al. Prediction of treatmentrelated
toxicity and outcome with geriatric assessment in elderly patients
with solid malignancies treated with chemotherapy: a systematic
review. Ann Oncol. 2014;25:1914-1918.
48. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab
for node-negative, HER2-positive breast cancer. N Engl J Med.
2015;372:134-141.
49. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in
HER2-positive breast cancer. N Engl J Med. 2011;365:1273-1283.
50. Vaz-Luis I, Keating NL, Lin NU, et al. Duration and toxicity of adjuvant
trastuzumab in older patients with early-stage breast cancer: a
population-based study. J Clin Oncol. 2014;32:927-934.
51. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention
of cardiotoxicity with chemotherapy: a systematic review and metaanalysis.
Eur J Cancer. 2013;49:2900-2909.
52. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-
positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.
53. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized
trial of primary endocrine therapy versus chemotherapy in postmenopausal
patients with estrogen receptor-positive breast cancer. Cancer.
2007;110:244-254.
54. Gianni L, Pienkowski T, Im YH, et al. Effıcacy and safety of neoadjuvant
pertuzumab and trastuzumab in women with locally advanced, inflammatory,
or early HER2-positive breast cancer (NeoSphere): a randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.
55. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in
combination with standard neoadjuvant anthracycline-containing and
anthracycline-free chemotherapy regimens in patients with HER2-
positive early breast cancer: a randomized phase II cardiac safety study
(TRYPHAENA). Ann Oncol. 2013;24:2278-2284.
56. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric
Oncology consensus on geriatric assessment in older patients with cancer.
J Clin Oncol. 2014;32:2595-2603.
57. Sattar S, Alibhai SM, Wildiers H, et al. How to implement a geriatric
assessment in your clinical practice. Oncologist. 2014;19:1056-1068.
58. Fried TR, Bradley EH, Towle VR, et al. Understanding the treatment
preferences of seriously ill patients. N Engl J Med. 2002;346:1061-
1066.
59. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without
breast irradiation in women 50 years of age or older with early breast
cancer. N Engl J Med. 2004;351:963-970.
60. Kunkler IH, Williams LW, Jack W, et al. The PRIME II trial: Wide local
excision and adjuvant hormonal therapy postoperative whole
breast irradiation in women 65 years with early breast cancer managed
by breast conservation. San Antonio Breast Cancer Symposium.
2013;S2-S01.
61. Potter R, Gnant M, Kwasny W, et al. Lumpectomy plus tamoxifen or anastrozole
with or without whole breast irradiation in women with favorable
early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:334-340.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 55